To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants

Bristol-Myers Squibb33 enrolled

Overview

Access the safety, tolerability, and pharmacokinetics of BMS-986177 in healthy Japanese participants after multiple doses are administered.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

QUADRUPLE

Enrollment

Conditions

Thrombosis

Interventions

BMS-986177DRUG

Oral Suspension

Matched PlaceboOTHER

Oral Suspension

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Participants must be first-generation Japanese (born in Japan and not living outside of Japan for \> 10 years; both parents must be ethnically Japanese) * Body Mass Index 18.0 to 25.0 kg/m2, inclusive * Women must not be of nonchildbearing potential (cannot become pregnant) Exclusion Criteria: * Any significant acute or chronic medical illness * History of allergy to BMS-986177 or other factor Xia inhibitors and/or formulation excipients or history of any significant drug allergy (such as anaphylaxis or hepatotoxicity) * History or evidence of abnormal bleeding or coagulation disorder Other protocol defined inclusion and exclusion criteria apply

Locations (1)

West Coast Clinical Trials

Anaheim, California, United States